Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Cannabidiol for the treatment of psychosis in Parkinson's disease

Texto completo
Autor(es):
Zuardi, A. W. [1] ; Crippa, J. A. S. [1] ; Hallak, J. E. C. [1] ; Pinto, J. P. [1] ; Chagas, M. H. N. [1] ; Rodrigues, G. G. R. [1] ; Dursun, S. M. [2] ; Tumas, V. [1]
Número total de Autores: 8
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neuropsychiat & Med Psychol, Sao Paulo - Brazil
[2] Univ Alberta, Dept Psychiat, Edmonton, AB - Canada
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: JOURNAL OF PSYCHOPHARMACOLOGY; v. 23, n. 8, p. 979-983, NOV 2009.
Citações Web of Science: 113
Resumo

The management of psychosis in Parkinson's disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective effect of Cannabidiol (CBD) has been suggested. Therefore, the aim of the present study was to directly evaluate for the first time, the efficacy, tolerability and safety of CBD on PD patients with psychotic symptoms. This was an open-label pilot study. Six consecutive outpatients (four men and two women) with the diagnosis of PD and who had psychosis for at least 3 months were selected for the study. All patients received CBD in flexible dose (started with an oral dose of 150 mg/day) for 4 weeks, in addition to their usual therapy. The psychotic symptoms evaluated by the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire showed a significant decrease under CBD treatment. CBD did not worsen the motor function and decreased the total scores of the Unified Parkinson's Disease Rating Scale. No adverse effect was observed during the treatment. These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD. (AU)

Processo FAPESP: 02/13197-2 - Participação do glutamato e óxido nítrico na fisiopatogenia de distúrbios neuropsiquiátricos
Beneficiário:Francisco Silveira Guimaraes
Linha de fomento: Auxílio à Pesquisa - Temático